斯帕森坦:一流的双重内分泌素和 ангиотензинII受体对抗剂
1Renal Program, Fraser Health Authority, Surrey, BC, Canada.
The Annals of pharmacotherapy
|September 14, 2023
概括
斯帕森坦有效地降低了IgA脏病 (IgAN) 和焦点细分结核硬化 (FSGS) 的蛋白尿症. 这种新疗法为高风险患者提供了一个有前途的选择,在等待长期安全性和疗效数据之前.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 免疫球蛋白A脏病 (IgAN) 和焦点细分质硬化 (FSGS) 是导致进展性病的主要原因.
- 目前针对Igan和FSGS的管理指南侧重于支持性护理和免疫抑制.
- 需要新的治疗药物来减缓疾病的进展,并保持功能.
研究的目的:
- 对Igan和FSGS的当前管理准则进行审查.
- 评估对新型双内末和血管素受体抗剂sparsentan的证据.
- 讨论斯帕森坦在Igan和FSGS治疗领域的潜在作用.
主要方法:
- 通过使用MEDLINE,EMBASE和clinicaltrials.gov.gov进行了全面的文献搜索.
- 包括评估sparsentan在人类中的药理学,药理动力学,疗效和安全性的研究.
- 还提取了监管机构 (FDA) 和制造商信息的数据.
主要成果:
- 与伊尔贝萨坦相比,斯帕森坦在Igan和FSGS队列中显示出尿蛋白与肌素比率 (UPCR) 的显著降低.
- 在IGAN中,sparsentan在36周后实现了-49.8%的UPCR降低,而irbesartan则降低了-15.1%.
- 在FSGS中,sparsentan在8周后显示了-44.8%的UPCR降低,而irbesartan则降低了-18.5%. 常见的不良事件包括低血压和;短期肝毒性似乎与伊尔贝萨坦可比.
结论:
- 斯帕森坦为患有IgAN且患有进展性病高风险的患者提供了一种新的治疗选择.
- 美国食品和药物管理局 (FDA) 已经批准了Igan中的sparsentan.
- 关于功能和安全性的长期数据正在等待,对于继续获得FDA批准和临床采用至关重要.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
197
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
197
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
776
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
776
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
460
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
687
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
687
01:25Antihypertensive Drugs: Direct Renin Inhibitors
677
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
677
01:30Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12